Attovia Therapeutics Inc.
ATTO | NASDAQ
$21.30
-$0.84 (-3.79%)
At close: Sep 21, 2026, 4:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q1 2025 Mar 30, 2025 |
|---|---|---|---|
Revenue | 450K | n/a | n/a |
Cost of Revenue | 246K | 242K | 143K |
Gross Profit | 204K | -242K | -143K |
Operating Income | -21.8M | -19.96M | -16.1M |
Interest Income | 1.14M | 1.33M | 1.13M |
Pretax Income | -20.69M | -18.66M | -15.15M |
Net Income | -20.69M | -18.66M | -15.15M |
Selling & General & Admin | 3.06M | 2.97M | 4.11M |
Research & Development | 18.95M | 16.75M | 11.86M |
Other Expenses | n/a | n/a | n/a |
Operating Expenses | 22.01M | 19.71M | 15.96M |
Interest Expense | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 22.25M | 19.96M | 16.1M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 45.65M | 38.53M | 38.53M |
Shares Outstanding (Diluted) | 45.65M | 38.53M | 38.53M |
EPS (Basic) | -0.45 | -0.48 | -0.40 |
EPS (Diluted) | -0.45 | -0.48 | -0.40 |
EBITDA | -21.56M | -19.71M | -15.96M |
EBIT | -21.8M | -19.96M | -16.1M |
Depreciation & Amortization | 246K | 242K | 143K |
Add to Watchlist
Select watchlists to add or remove ATTO